New cocktail of drugs takes on advanced lung cancer

NCT ID NCT07309276

Recruiting now Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of four drugs (JS212, JS207, Toripalimab, and JS213) in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 864 participants will receive the drugs by IV every three weeks. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS212, JS207, Toripalimab, JS213 (drugs given by IV infusion every 21 days)
What this could lead to: If successful, this could offer a new combination treatment option to shrink tumors or slow disease progression in advanced lung cancer.
What could go wrong: This is an early-phase (Phase II) trial, so the combination may not work better than existing treatments. Side effects from the drug combination are possible and being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG CANCER

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.